Roy Fleischmann, MD: Long-Term Safety, Efficacy of Upadaciti

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

Related Keywords

Dallas , Texas , United States , Roy Fleischmann , European Congress , Metroplex Clinical Research Center , American College Of Rheumatology , Texas Southwestern Medical Center , Medical Director , American College ,